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ABSTRACT 
Biomaterial-associated infections represent a significant clinical problem, and 
treatment of these microbial infections is becoming troublesome due to the 
increasing number of antibiotic-resistant strains. Here, we report a naturally 
functionalized bacterial polyhydroxyalkanoate (PHACOS) with antibacterial 
properties. We demonstrate that PHACOS selectively and efficiently inhibits the 
growth of methicillin-resistant Staphylococcus aureus (MRSA) both in vitro and 
in vivo. This ability has been ascribed to the functionalized side chains 
containing thioester groups. Significantly less (3.2-fold) biofilm formation of S. 
aureus was detected on PHACOS compared to biofilms formed on control 
poly(3-hydroxyoctanoate-co-hydroxyhexanoate) and poly(ethylene 
terephthalate), but no differences were observed in bacterial adhesion among 
these polymers. PHACOS elicited minimal cytotoxic and inflammatory effects on 
murine macrophages and supported normal fibroblast adhesion. In vivo 
fluorescence imaging demonstrated minimal inflammation and excellent 
antibacterial activity for PHACOS compared to controls in an in vivo model of 
implant-associated infection. Additionally, reductions in neutrophils and 
macrophages in the vicinity of sterile PHACOS compared to sterile PHO implant 
were observed by immunohistochemistry. Moreover, a similar percentage of 
inflammatory cells was found in the tissue surrounding sterile PHACOS and S. 
aureus pre-colonized PHACOS implants, and these levels were significantly 
lower than S. aureus pre-colonized control polymers. These findings support a 
contact active surface mode of antibacterial action for PHACOS and establish 
this functionalized polyhydroxyalkanoate as an infection-resistant biomaterial. 
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1. Introduction 
Bacterial infections are a major cause of morbidity and mortality worldwide 
and many infections can be attributed to Staphylococcus species [1]. The acute 
pathogenic properties of Staphylococcus aureus [2] as well as its ability to 
cause chronic infections and persist on medical implants or host tissues is 
recognized as a significant healthcare threat [3]. In fact, the ability of S. aureus 
to form biofilms has been linked to the persistence of chronic infections [1]. 
Methicillin-resistant S. aureus (MRSA), which have developed resistance to 
virtually all -lactam antibiotics [4], are a major concern. MRSA are especially 
troublesome in hospitals, prisons, schools, and nursing homes where patients 
with open wounds, invasive devices, and/or weakened immune systems are at 
high risk of infection [5]. 
Although the bactericidal properties of some polymers were reported as 
early as in 1965 [6], antimicrobial polymers represent a class of increasingly 
important materials that may represent an alternative to current biocides and, in 
some cases, even to antibiotics. In the past decade, the number of Food and 
Drug Administration (FDA)-approved disinfecting polymers has significantly 
increased, supporting the compelling need for alternatives to antibiotics and 
environmentally critical disinfectants [7]. Antimicrobial surfaces that prevent 
growth of biofilms are considered an effective strategy to inhibit the 
establishment and spread of microbial infections. Such surfaces either repel 
microbes —so they cannot attach to it— or kill them in their vicinity [7].  
Most polymeric and biodegradable systems currently used in medicine are 
based on poly(lactic acid), poly(glycolic acid) and on their copolymers [8]. One 
of the leading candidates with potential applications in the medical field is the 
group of naturally produced bacterial polyesters or poly([R]-3-
hydroxyalkanoates) (PHAs) that constitute a large class of biodegradable 
biopolymers that show minimal tissue toxicity [9]. The physical and mechanical 
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properties of PHAs are significantly influenced by their monomer composition 
and chemical structure [10]. Some short-chain-length PHAs may be too rigid 
and brittle and lack the superior mechanical properties required for biomedical 
and packaging film applications. In contrast, medium-chain-length PHAs (mcl-
PHAs) may be elastomeric but have very low mechanical strength. Therefore, 
the physical and mechanical characteristics of microbial polyesters need to be 
diversified and improved for packaging materials, tissue engineering, and other 
specific applications [11,12].  
Recently, we produced poly-3-hydroxy-acetyllthioalkanoate-co-3-
hydroxyalkanoate (PHACOS), a new second generation polymer containing 
thioester groups in the side chain (Fig. 1a) [13]. In this work, we analyzed the 
antimicrobial properties of PHACOS compared to the non-reactive poly(3-
hydroxyoctanoate-co-hydroxyhexanoate) (PHO) and poly(ethylene 
terephthalate) (PET) in in vitro and in vivo models. 
 
2. Materials and methods 
2.1. Polymer preparation, disk fabrication, and endotoxin analysis 
PHACOS and PHO polymers (Fig. 1) were prepared as previously reported 
[13] and kindly provided by Biópolis, S.L. To determine the monomer 
composition of PHA, gas chromatography-mass spectrometry and nuclear 
magnetic resonance analyses were carried out [13]. The monomer content of 
PHACOS was 29.7% of non-functionalized monomers [17.5% of 3-
hydroxyoctanoate (OH-C8), 10.3% of 3-hydroxydecanoate, and 1.9% of 3-
hydroxyhexanoate (OH-C6) monomers] and 70.3% of functionalized monomers 
(46.4% of 3-hydroxy-6-acetylthiohexanoate and 23.9% of 3-hydroxy-4-
acetylthiobutanoate monomers). PHO consisted of 8.5% OH-C6 and 91.5% 
OH-C8. An optimized downstream processing was applied to eliminate 
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endotoxins [14]. Briefly, 1 g of PHA was dissolved in 100 mL of chloroform at 40 
°C under vigorous stirring, the suspension was pressure filtered and the 
polymer was precipitated by addition of non-solvent methanol. Finally, the 
polymer was dried under vacuum at 40 °C for 48 h. This procedure was 
repeated two times to obtain mcl-PHA with endotoxin units (EU) 20 EU g–1, in 
compliance with the endotoxin requirements for biomedical applications [14]. 
The endotoxin content was measured using a Limulus amebocyte lysate (LAL)-
test (Pyrogent Plus Single Test Kit, Lonza). The values of PHACOS and PHO 
endotoxicity were <12 EU g–1 and <15 EU g–1, respectively.  
Poly(ethylene terephthalate) (PET) disks were coated with PHACOS or 
PHO by solvent-casting. Polymeric materials dissolved in chloroform (2% w/v) 
were applied over sterile, endotoxin-free PET disks (6 mm diameter; kindly 
supplied by ACCIONA, Barcelona, Spain), in a dust-free atmosphere. The 
coatings were allowed to dry for 72 h at room temperature and the resulting 
PHACOS-coated disks (PHACOS disks), PHO-coated disks (PHO disks) and 
control PET disks were sterilized with ethylene oxide at 40 °C. 
2.2. Bacterial strains, media and pre-culture suspensions 
The bacterial strains used in this study are listed in Table 1. Bacteria were 
transferred from a frozen stock (–80 °C in 15% of glycerol) to screw-capped test 
tubes containing nutrient agar (Nutrient Broth DifcoTM, NB, supplemented with 
1.5% agar) and incubated at 37 °C for 16–24 h. Afterwards, bacteria were 
transferred onto fresh slant culture medium and incubated at 37 °C for 16–20 h. 
These were designated hereafter as ―pre-cultured bacteria‖. The phenotypes 
including the MICs to resistance to common antibiotics of S. aureus (MRSA) are 
shown in Table S1. 
2.3. Biofilm formation on mcl-PHAs 
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To determine the capacity of polymers to prevent bacterial biofilm 
formation, Staphylococcus aureusT and Pseudomonas aeruginosa CECT 4122 
were used. Pre-cultured bacteria were incubated in trypticase soy broth (TSB) 
supplemented with 0.3% glucose and 0.4% yeast extract (enriched TSB or e-
TSB) with shaking, at 37 °C for 20 h. Bacterial concentration was estimated 
spectrophotometrically at 600 nm. Biofilm formation was carried out (in 
triplicate) as follows: endotoxin-free, sterile PHO disks, PHACOS disks or 
control PET disks were placed in 24-flat bottom well plates (Falcon, Becton 
Dickinson) and each well was inoculated with 1 mL of a 1/100 dilution in TSB of 
a saturated culture previously grown in e-TSB. Plates were incubated under 
static conditions for 16 h at 37 °C and bacterial growth was determined by 
measuring the optical density at 595 nm (OD595) using a plate reader 
(microplate absorbance reader 2020; Anthos Labtec Instruments GmbH). The 
ability of bacteria to form biofilms was analyzed by environmental scanning 
electron microscopy (ESEM), crystal violet staining [15], and colony-forming 
units (CFU) counting.  
ESEM was employed to examine the formation of biofilm on PHACOS, 
PHO and PET control disks. Disks were washed three times with distilled sterile 
water and fixed with 2.5% glutaraldehyde for 2 h at room temperature. The 
dried samples were mounted on aluminum stumps and sputter-coated with 
chromium before examination under an ESEM apparatus (Philips XL 30) at an 
accelerating voltage of 15 kV. 
For CFU counting, disks were washed with distilled water and the bacteria 
in the biofilms were mechanically removed from the disk using a disposable, 
sterile micropipette tip. CFU were determined by plating serial dilutions on 
Lysogeny Broth (LB) agar plates [16] and incubation at 37 °C for 24 h. 
2.4. Bacterial adhesion to polymers 
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For adhesion experiments, inocula were prepared by suspending pre-
cultured bacteria in 2 mL of 1/500 (v/v) diluted NB. Bacterial suspensions (1–2  
108 CFUs mL–1) were placed on PHACOS, PHO and control PET disks and 
incubated at 37 °C for 24 h. After rinsing, adherent bacteria were stained with 
the LIVE/DEAD BacLight bacterial viability kit L-13152 (Invitrogen-Molecular 
Probes) following the manufacturer’s instructions. Samples were visualized with 
a Zeiss Axioplan Universal epifluorescence microscope operated for incident-
light fluorescence and contrasting techniques of bright field and phase contrast. 
Micrographs were recorded with a digital camera Leica DFC350FX.  
2.5. Measurement of the antimicrobial activity of PHACOS and PHO 
Antibacterial activity was determined according to the ISO 22196:2011 
protocol (http://www.iso.org/iso/catalogue_detail.htm?csnumber=54431), with 
minor modifications. Each disk was placed into a separate sterile Petri dish with 
the test surface facing up and wet filter paper beneath to maintain a relative 
humidity 90%. Test inoculums (6.2–25.0  103 CFU cm–2) prepared in 1/500 
diluted NB were placed onto the polymers without cover film and incubated at 
37 °C for 24 h. Each material was tested in triplicate. Non-coated PET disks 
were used as controls for determination of bacterial viability. Samples were 
analyzed at 0 h and 24 h. After incubation, disks were washed with 1 mL of 
phosphate-buffered saline, pH 7.2 (PBS). The number of colonies recovered 
from PET disks at 0 h was used to determine the recovery rate of the bacteria 
from the disks under investigation. Antibacterial activity was calculated as the R 
value. R = 0.0 means that the logarithm of number of viable cells in the sample 
disk after 24 h is identical to that of control disk at the same time point, whereas 
R = 1.0 means 10-fold less viable cells recovered from sample disk after 24 h 
compared with the control PET disk. 
2.6. Determination of minimal inhibitory concentration (MIC) 
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The minimal inhibitory concentration (MIC) of polymer precursors 6-
acetythiohexanoic acid (545554, Sigma-Aldrich), octanoic acid (C5038, Sigma-
Aldrich) and hexanoic acid (P9767, Sigma-Aldrich) was determined by 
microdilution assays [18]. Stock solutions (60 mM) of each compound were 
prepared in PBS and serial dilutions were made in Muller-Hinton broth II (MHB 
II, Becton Dickinson). 
2.7. In vitro cytocompatibility 
2.7.1. Cell cultures 
Cellular toxicity was evaluated using either murine RAW 264.7 
macrophages (ECACC, Sigma P11) or BALB 3T3 fibroblasts (ATCC, CCL-163, 
P12), while inflammatory activity was monitored only on RAW 264.7 cells and 
effects on cell proliferation only on fibroblasts BALB 3T3. Cells were cultured in 
Dulbecco´s modified Eagle´s medium (DMEM) supplemented with HEPES (for 
BALB 3T3 cells) or sodium pyruvate (110 mg L–1; for RAW 264.7 cells), and 
10% fetal bovine serum (FBS), 100 units mL–1 penicillin, 100 µg mL–1 
streptomycin and 200 mM L-glutamine (complete medium). A humidified 
atmosphere at 37 °C with 5% CO2 and 95% of air was used for cell cultures 
growth. 
2.7.2. MTT assay 
The in vitro effects of products released from the polymers on cellular 
viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay [19]. PHO, PHACOS or control PET 
disks were immersed in 5 mL of FBS-free DMEM and placed on a roller mixer at 
37 °C. The medium was withdrawn at different time points and replaced with 
fresh medium. All these ―extracts‖ were obtained under sterile conditions.  
RAW 264.7 and BALB 3T3 cells were seeded at 2  105 cells mL–1 and 105 
cells mL–1, respectively, in a sterile 96-well culture plate and grown to 
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confluence. The culture medium was replaced with the corresponding extract 
and incubated at 37 °C for 24 h in humidified air with 5% CO2. Afterwards, cell 
viability was determined by adding MTT reagent (0.5 mg/mL in PBS) for 4 h at 
37 °C. Excess medium and MTT reagent were withdrawn and dimethylsulfoxide 
was added to solubilize the formazan crystals formed in viable cells. The OD570 
(test wavelength) and OD630 (reference wavelength) were determined using a 
microplate reader (Biotek SYNERGY-HT). Cell viability (CV) was calculated 
from equation: CV (%) = 100  (ODS – ODB)/ODC, where ODS, ODB and ODC 
are, respectively, the optical density of formazan production for the sample, 
blank (DMEM without cells), and control. 
2.7.3. Griess assay 
The inflammatory activity of polymers was investigated using a nitric oxide 
inhibitory assay [20]. Briefly, RAW 264.7 cells were seeded in 96-well plates at 
a density of 2  105 cells mL–1 and incubated at 37 °C for 24 h. After incubation, 
the corresponding extracts were added. Control wells received 
lipopolysaccharide (LPS) (1 mg mL–1) and cells were incubated for 24 h. The 
nitrite concentration was determined by the Griess reaction [21]. Aliquots (100 
µL) of the supernatant from RAW 264.7 cells were reacted with 100 µL of 
Griess reagent [1:1 mixture of 0.1% N-(1-naphthyl) ethylenediamine in water 
and 1% sulphanilamide in 5% phosphoric acid] in a 96-well plate and the OD548 
was recorded. The nitrite concentration was calculated from a calibration curve 
previously obtained using known NaNO2 concentrations. Data were expressed 
as the percentage of NO production. 
2.7.4. Cell proliferation assay 
The Alamar Blue (AB) assay was performed to monitor cell metabolic 
activity. BALB 3T3 cells were seeded at a density of 8  104 cells mL–1 over the 
disks placed in 24-well plates and grown for 24 h. To each specimen 1 mL of 
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AB dye (10% AB solution in phenol red-free DMEM medium) was added and 
after 4 h of incubation 100 µL from each test sample was transferred to a 96-
well plate to determine OD530 (excitation) and OD590 (emission). Then, to 
continue monitoring of cell growth disks were washed twice with PBS and 1 mL 
of culture medium was added. The assay was repeated at defined time points 
(1, 5 and 10 d).  
2.7.5. Cell morphology  
For determination of cell morphology, PHO, PHACOS and control PET 
disks were placed in a 24-well tissue-culture plate. BALB 3T3 cells (8  104 cells 
per well) were added and allowed to attach at 37 °C. Cell morphology was 
examined by ESEM (see above). 
2.8. In vivo responses and anti-bacterial effects 
2.8.1. Preparation of hydro-indocyanine green 
Hydro-indocyanine green (H-ICG) was synthesized from ICG (Acros 
Organics) by reduction with sodium borohydride as described [22]. Briefly, 2 mg 
of dye was dissolved in 4 mL of methanol and reduced with 2–3 mg of sodium 
borohydride (Aldrich). The solvent was removed using a rotary evaporator 
(Rotavapor R-210, BUCHI Labortechnik AG, Switzerland). The dye was 
nitrogen capped and stored overnight at –20 °C. For bioimaging, the resulting 
solid was dissolved in sterile water to a final concentration of 1 mg mL–1 and 
filtered before use. 
2.8.2. Sample preparation, implantation and bioimaging  
Biomaterial disks were incubated for 30 min at 37 °C with the bacteria in 
1/500 diluted NB (1  104 CFU cm–2) under static conditions. After incubation, 
disks were placed in sterile containers. 
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National Institutes of Health (NIH) guidelines for the care and use of 
laboratory animals were followed [23]. All surgical procedures were approved by 
the Institutional Animal Care and Use Committee at the Georgia Institute of 
Technology. Sterile, endotoxin-free disks were implanted subcutaneously in the 
back of 6–8 weeks old male BALB/c mice (Jackson Laboratories) anesthetized 
by isofluorane. A single 1-cm incision was made on the dorsum proximal to the 
spine, and a subcutaneous pocket laterally spanning the dorsum was created. 
Sterile disks (two per mouse, one on either side of the spine) were implanted, 
and the incision was closed using sterile wound clips. Mice undergoing the 
same surgical procedure but receiving no biomaterial implants were used as 
sham controls to account for surgery-associated trauma/inflammation. The 
same procedure was followed for implants incubated with bacteria. 
For bioimaging of reactive oxygen species associated with biomaterial-
associated inflammation [24], 30 µL of H-ICG (1 mg mL–1 in sterile water) was 
injected near the vicinity of the implant at 1, 4 and 7 d post-surgery/implantation. 
Thirty minutes later, the whole body of the animal was scanned in an IVIS 
Lumina® bioimaging system (Xenogen). Biofluorescence was integrated using 
Living Image®software Version 3.1 (Xenogen).  
2.8.4. Implant analysis 
After euthanasia, disks were carefully explanted with the intact surrounding 
tissue to avoid disrupting the cell-material interface. For immunohistochemical 
staining, explants were embedded in optimal cutting temperature compound 
(Tissue-Tek) and cryosectioned at 10 µm. Fresh-frozen cryostat sections were 
incubated in 100 mM hydro-Cy5 (H-Cy5) for 45 min at 37 °C to stain for 
intracellular ROS. Afterwards, sections were fixed with 4% paraformaldehyde 
and stained with rat monoclonal antibodies (Abcam) against macrophage 
(CD68) or neutrophil (NIMP-R14) markers. Alexa Fluor 488-conjugated goat 
anti-mouse specific antibody (Invitrogen) was used as a secondary antibody. 
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Sections were mounted with antifade mounting media containing 4´,6-
diamidino-2-phenylindole (DAPI, Vector Labs) and imaged under a Nikon C1 
imaging system. Five-six fields per sample were acquired and ImageJ software 
was used to count the fluorescent-labeled cells.  
2.9. Statistical analysis 
Statistical analysis was performed by two-way ANOVA using Tukey post-hoc 
test with P ≤ 0.05 considered signiﬁcant. For longitudinal ROS bioimaging 
studies, a two-way repeated measures ANOVA was used to account for the 
variance within subjects. Pair-wise comparisons were performed using 
Bonferroni post-hoc test with P ≤ 0.05 considered signiﬁcant. 
 
3. Results 
3.1. Biofilm formation by S. aureusT on PHACOS 
Previous studies had shown that the quality of bacterial biofilm on mcl-
PHAs varies depending on both bacterial strain and purity of the material 
supporting biofilm formation [25]. Based on this observation, we focused on 
studying the ability of S. aureusT and P. aeruginosa to form biofilms on 
PHACOS and PHO surfaces. ESEM showed less biofilm formed by S. aureusT 
than P. aeruginosa on PHACOS at 16 h, while the biofilms formed by either 
strain on PHO were similar. However, adhered cells were always observed in 
both polymers (Fig. 2a). S. aureusT formed 3-fold less biofilm than P. 
aeruginosa on PHACOS, whereas the biofilm formed on PHO was similar for 
both strains, as shown by crystal violet staining (Fig. 2b). Moreover CFU 
counting confirmed these results, showing that the S. aureusT biofilm on 
PHACOS contained 10% of the bacteria found in the P. aeruginosa biofilm (Fig. 
2c). Additionally, PHACOS had significantly less S. aureusT counts than PHO.  
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To determine whether the differences in biofilm formation on PHACOS 
resulted from differences in initial bacterial attachment, the number of adhered 
bacteria was analyzed by epifluorescence microscopy. In these experiments, 
bacteria were suspended in a 1/500 diluted NB medium and deposited on the 
PHACOS and PHO surfaces for 24 h. The lack of nutrients in the diluted 
suspension avoided biofilm formation but allowed testing the adhesion step of 
biofilm formation. There were no differences between the number of adherent 
S. aureusT cells to PHO and PHACOS (Fig. 3a,b), but the number of S. aureusT 
cells was lower than that of P. aeruginosa on both surfaces (PHO and 
PHACOS) (data not shown).  
We next examined whether PHACOS was capable of bacterial killing using 
the LIVE/DEAD BacLightTM kit (Fig. 3a,b). The percentage of viable S. aureusT 
on PHACOS was much lower (20%) than those on PHO (83%), suggesting that 
PHACOS possesses anti-staphylococcal activity.  
3.2. Antibacterial activity of PHACOS against MRSA 
We further analyzed the antibacterial activity of PHACOS following ISO 
22196:2011 standard protocol used to characterize the effectiveness of the 
antibacterial polymer. In these assays we compared the viability of nine Gram-
positive and two Gram-negative bacteria (Table 1) after contacting the 
PHACOS surface. Susceptibility to PHACOS was evident only in some Gram-
positive bacteria. Moreover, the antimicrobial activity of PHACOS was 
apparently restricted to S. aureus strains, including MRSA clinical isolates (R  
1.03) (Fig. 3c). However, when bacterial inocula exceeded 106 CFU cm–2, no 
anti-staphylococcal activity could be detected (data not shown), which 
suggested that a direct contact between bacteria and the polymer is a 
prerequisite for PHACOS antimicrobial activity. 
3.3. Antimicrobial activity dependence on thioester group  
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To examine whether the antimicrobial activity of PHACOS was due to the 
presence of thioester groups in the side chain of the polymer, the antimicrobial 
activity of fatty acids with structures similar to PHACOS monomers (octanoic, 
hexanoic and 6-acetylthiohexanoic acids) was studied using S. aureusT. The 
MIC of 6-acetylthiohexanoic acid (40 M) was 15-fold lower than that of 
hexanoic acid (0.7 mM). Moreover, octanoic acid was less harmful for 
staphylococci (MIC = 3 mM) than hexanoic acid (data not shown). These results 
suggested that thioester groups play a relevant role on the microbicidal activity 
of PHACOS. 
3.4. In vitro mammalian cell adhesion properties and cytotoxicity of PHACOS 
The viability and metabolic functions of mammalian cells in culture were 
measured using the MTT assay. This test is dependent on the intact activity of 
the mitochondrial succinate dehydrogenase that may be impaired after 
exposure of cells to toxic species. No detectable mitochondrial damage could 
be found for any of the tested surfaces as the viability of macrophages in 
presence of extracts prepared from the polymers was approximately 100% (Fig. 
4a,b). Similarly, no changes in metabolic activity were detected among PET, 
PHO, and PHACOS for fibroblasts (Fig. 4c). 
To measure the inflammatory activity of the polymers, a NO inhibitory assay 
was employed. NO is a mediator and regulator in many pathological reactions, 
especially in acute inflammatory responses [20]. Pro-inflammatory agents, such 
as LPS, increase NO production in macrophages through activation of inducible 
NO synthase [26]. No differences in NO activity was measured for extracts from 
PHO and PHACOS compared to the PET control (Fig. 4d), even though the 
LPS positive control produced robust increases in NO activity. Finally, we 
examined whether PHACOS supports mammalian cell adhesion and 
proliferation using the Alamar Blue assay. PHACOS supported equivalent levels 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16 
 
of cell activity as the PET control, whereas PHO supported reduced cell activity 
(Fig. 5). Moreover, the morphology and growth of fibroblasts was normal on all 
tested surfaces after 7 d (data not shown). 
3.5. In vivo inflammatory responses and antibacterial activity  
We have recently established the use of H-ICG to evaluate the production 
of ROS linked to implant-associated inflammation [24]. PET disks coated with 
either PHO or PHACOS were implanted subcutaneously in mice and we 
monitored ROS associated with inflammatory responses to implanted 
biomaterials via a single local injection of H-ICG dye at the vicinity of the 
surgical site. After 30 min animals were imaged via an IVIS fluorescence 
imaging system. Mice undergoing the same surgical procedure, but receiving no 
implants were used as sham controls to account for surgery-associated 
trauma/inflammation, whereas some mice received dye injection but no surgery 
(dye-only control). As expected, mice receiving biomaterial implants exhibited 
increases in fluorescence signal over time that were higher than the dye-only 
control (Fig. 6). Notably, no significant differences in fluorescence signals were 
observed among sterile PHACOS and PHO implants and the sham control. This 
result indicates minimal inflammation associated with these polymers.  
We also examined whether PHACOS exhibits antimicrobial properties in 
vivo. After a short incubation with S. aureusT, biomaterial disks were implanted 
subcutaneously as described above. Implant-associated inflammation was 
monitored using H-ICG and in vivo imaging. Significantly higher ROS signals 
were observed for PHO disks incubated with bacteria compared to sterile PHO 
disks (Fig. 6). These increased levels reflect the increased inflammatory 
response associated with the infected implant. Remarkably, PHACOS disks 
incubated with bacteria exhibited significantly lower ROS signal compared to 
bacteria-incubated PHO disks, and the ROS levels for bacteria-incubated 
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PHACOS disks were not different from the levels for sterile PHACOS implants. 
Taken together, these results demonstrate that PHACOS effectively controls 
biomaterial-associated infections by S. aureus in an in vivo model of device-
related infection.  
Following imaging, mice were sacrificed and the disks were retrieved along 
with implant-associated tissues. Using immunohistochemistry, we analyzed 
macrophage (CD68+, green) and neutrophil (NIMP-R14+, green) recruitment to 
the implant (Fig. 7a,c). Additionally, total cell number (DAPI stained, blue) was 
compared with the number of inflammatory cells (Fig.7a,c,e). Higher recruitment 
of inflammatory cells was found to the vicinity of the sterile PHO implants (76% 
of total cell number) compared with sterile PHACOS implants (62% of total cell 
number) at 14 d post-implantation. Moreover, when the implants were pre-
colonized with S. aureusT, the influx of inflammatory cells was higher in the 
vicinity of the PHO implant (82% of total cell number) than around PHACOS 
implant (65% of total cell number). It is worth noting that there was a statistically 
significant difference (P < 0.05) between macrophage recruitment to S. aureusT 
pre-colonized PHO (38% macrophages) and S. aureusT pre-colonized PHACOS 
(31% macrophages) implant. Remarkably, there was no statistically significant 
difference (P = 0.05) in macrophage recruitment between S. aureusT pre-
colonized PHACOS (31% macrophages) and sterile PHACOS implants (29% 
macrophages). Moreover, significant differences (P < 0.05) in neutrophil 
recruitment to sterile PHO (43% neutrophils) and sterile PHACOS (33% 
neutrophils) implants, as well as between S. aureusT pre-colonized PHO (44% 
neutrophils) and S. aureusT pre-colonized PHACOS implants (34% neutrophils) 
were observed. Taken together, obtained results indicate mild inflammatory 
response to sterile PHACOS implant and its antimicrobial effectiveness in vivo. 
In addition, we co-stained for intracellular ROS activity using hydro-Cy5 (H-
Cy5) as previously described [27]. Importantly, co-staining analysis for 
inflammatory cell markers and ROS activity demonstrated that neutrophils and 
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macrophages are primarily responsible for the ROS activity associated with the 
implant (Fig. 7b,c). As expected, neutrophils are mainly responsible for ROS 
activity, when the implants are pre-colonized with S. aureusT (Fig. 7f).   
 
4. Discussion 
Biomaterial-related infections represent a growing healthcare problem [28], 
as bacterial colonization and biofilm development can be prelude to both 
systemic infection and malfunction of implanted device. An additional 
confounding problem is an increasing incidence of multi-drug resistant bacteria 
(also known as ―superbugs‖). Decrease in the number of effective antibiotics, as 
well as the slower pace of development of new antibiotics to replace those that 
become ineffective is an emerging threat to public health [29]. In addition, 
current actions to prevent antimicrobial resistance are not sufficient. 
Tremendous efforts have focused on developing compounds that, not only 
show high efficacy, but also are less susceptible to resistance development in 
the bacteria. The high incidence and rapid emergence of resistance to 
antibiotics in various Gram-positive cocci makes Gram-positive pathogens a 
major health hazard. In addition, Klein et al. [5] reported that during 1999–2006 
the percentage of MRSA increased >90%, or ≈10% a year, in outpatients 
admitted to US hospitals. The development of newer, stronger antibiotics which 
can overcome these acquired resistances is still a scientific challenge because 
new modes of antimicrobial action are required. Antimicrobial polymers have 
emerged as a promising candidate for further development as antimicrobial 
agents with decreased potential for resistance development [30]. 
We explored the possibilities of applications as biomedical devices made of 
the recently synthesized second generation polymer PHACOS. One of the 
peculiarities of this naturally produced bacterial polyester is the presence of 
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thioester groups in the side chain of the polymer. We have shown that thioester 
groups play a crucial role in polymer activity against S. aureus. Related to this, 
we demonstrate the unique property of this P. putida biopolyester to be active 
against other bacterial species. Nevertheless, further modification of PHACOS 
for fine tuning of its activity and specific applications could be easily achieved 
using its functionalized side chains to incorporate different active molecules. In 
addition, we observed a clear inhibition of S. aureus biofilm development on 
PHACOS.  
It has been estimated that biofilms are associated with 65% of nosocomial 
infections [31]. Biofilm formation on biomaterials can generally be divided into 
two main stages: bacterial adhesion, which depends on surface properties of 
both substrate and cells, and increase of biofilm mass, which depends on initial 
attachment and specific growth rate of attached cells [25]. Mauclaire et al. [25] 
provided an evaluation for the potential of pathogenic biofilm development on 
non-functionalized mcl-PHAs showing better attachment of Escherichia coli to 
mcl-PHA coatings than S. aureus. Moreover, impurity elimination of the 
biopolyester coating drastically limits biofilm formation [25]. A significant 
correlation was observed between bacterial attachment and roughness for S. 
aureus, a bacterium which is known to be sensitive to surface irregularities [32]. 
Although PHACOS shows higher roughness than PHO (data not shown) no 
increase in attachment of S. aureus cells to PHACOS was observed. Moreover, 
S. aureusT biofilm formation was decreased on PHACOS when compared to 
PHO.  
Novel approaches for the development of antimicrobial polymers are an 
important area of research and many reports have been published referring to 
the synthesis of macromolecules that are inherently antimicrobial (biocidal 
polymers). These are usually positively charged macromolecules that interact 
with microbial cells that generally carry a negative net charge at the surface due 
to their membrane proteins, teichoic acids of Gram-positive bacteria, and 
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negatively charged phospholipids at the outer membrane of Gram-negative 
bacteria. Cationic polymers, biocide-releasing polymers and antimicrobial 
peptides have been the main focus (for reviews, see references [7,30,33,34]). 
These subjects have attracted much attention and significant improvements in 
understanding of their essential physiochemical properties and mode of action 
have been made. Todate neither the antibacterial activity of PHAs nor their anti-
adherent properties on bacteria were reported. However, a low, but definite, 
antibacterial activity of monomers derived from PHAs (R-3-hydroxycarboxylic 
acids) has been demonstrated [35,36]. 
This work suggests that PHACOS acts as contact active surface and 
therefore could be considered as biocidal polymer. However, taking into 
account the notable antibacterial activity of 6-acetylthiohexanoic acid, we 
cannot discard the possibility that its hydroxyl-derivates (monomers) may be the 
real polymeric biocide, as the polymerization of active monomeric units leads to 
an antimicrobial polymer, although we have not observed any in vitro 
degradation of the polymer, at least during one month (data not shown). In this 
respect, a homopolymer of thioester monomers would be preferable to reach 
the maximum antimicrobial activity of PHACOS material. The composition of the 
biopolymer in terms of incorporation of functionalized or non functionalized 
monomers can be fully controlled by the bacterium culture conditions and by 
engineering the metabolic and regulatory networks of Pseudomonas putida. 
Presently, some gene transcription regulatory restrictions cannot be avoided 
and non-substituted fatty acids must be added to the culture medium for 
PHACOS accumulation [13]. It is expected that the more antimicrobial thioester 
ligands linked to the polyester back bone, the more effective biocide activity of 
PHACOS. However, the percentage of thioester monomers in the polymer used 
in this study is already 77% and no activity was observed against other bacteria 
than S. aureus.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
 
Several antibacterial polymers are known to be selective against S. aureus 
over other species. Cationic polymers including polynorbornenes [37], 
oligolysins [38], and chitosan [39] all showed selective activity against S. aureus 
over E. coli. Although the chemical structures of these polymers are quite 
different from each other, the cationic functionality appears to be in common, 
which may be the key determinant in the activity against S. aureus. Recently, 
Gibney et al. demonstrated that commercially available unmodified 
polyethyleneimines (PEIs) with branched structures (Mr = 500–12,000) are 
antibacterial with superior activity against S. aureus than against E. coli [40]. 
The finding that the single strain of S. epidermidis tested, i.e., the type strain, 
was not killed by PHACOS may be explained by a strain-specific effect or, most 
probably, by differences between S. aureus and S. epidermidis. Notably, S. 
epidermidis (but not S. aureus) produces a surface-attached polymer (poly--
DL-glutamic acid) that protects the bacterium from antimicrobial peptides and 
neutrophil phagocytosis [41]. Whether the presence of this polymer may be 
involved in the PHACOS resistance of coagulase-negative staphylococci (e.g., 
S. epidermidis) warrants further studies. The mode of action of certain polymers 
has been studied and defined [42-44]. Nevertheless, the precise mechanism(s) 
by which PHACOS decrease biofilm formation and kills bacteria is still a matter 
of debate. The recent review of Timofeeva et al. [45] thoroughly discusses the 
influence of relevant parameters, such as molecular weight, type and degree of 
alkylation, and distribution of charge on the bactericidal action of antimicrobial 
polymers. Therefore, there are many factors that should be investigated to 
unravel the mode of action of PHACOS.  
 Apart from the desirable antimicrobial properties, low inflammation is 
essential for the acceptance of an incorporated object by mammals [46]. Tests 
have shown that PHAs provoke mild host reactions when implanted, which is 
not surprising when considering the fact that [R]-3-hydroxybutyric acid is a 
normal constituent of blood at concentrations between 0.3 and 1.3 mM [47] and 
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is also found in the cell envelope of eukaryotes [48]. Many successful studies 
using various animal models have clearly demonstrated that PHA, represented 
by poly(3-hydroxybutyrate), copolymer of 3-hydroxybutyrate and 3-
hydroxyvalerate, poly(4-hydroxybutyrate), poly([R]-3-hydroxyoctanoate (PHO) 
and copolymers of 3-hydroxybutyrate and 3-hydroxyhexanoate, possesses the 
biodegradability, thermoprocessibility and induce low inflammation and 
therefore are suitable for implant applications [9]. However, very few of naturally 
functionalized bacterial polyesters have been tested as biomaterials [49]. The  
biomedical applications of PHO and other mcl-PHAs have been recently   
reviewed [12]. Here we present results from an in vivo study on PHACOS 
antimicrobial activity and good host acceptance in terms of inflammatory 
response.  
5. Conclusions 
We describe a new and unexpected property of PHACOS, a second 
generation biopolymer, showing antibacterial activity specifically against S. 
aureus isolates including MRSA and decreasing S. aureusT biofilm formation. 
This ability has been ascribed to the functionalized side chains containing 
thioester groups. Furthermore, we show the possibility of PHACOS for 
biomedical applications as an implant material demonstrating its antimicrobial 
properties and minimal inflammation in vivo. 
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FIGURE CAPTIONS 
Fig. 1. Schematic representation of medium chain lenght PHAs chemical structure. (a) poly(3-hydroxy-6-
acetylthiohexanoateco-4-acetylthiobutanoate) PHACOS composed of functionalized (3-hydroxy-6-
acetylthiohexanoate and 3-hydroxy-4-acetylthiobutanoate monomers) and of non-functionalized monomers 
(3-hydroxyoctanoate, 3-hydroxydecanoate, and traces of 3-hydroxyhexanoate monomers). (b) poly(3-
hydroxyoctanoate-co-hydroxyhexanoate) PHO composed of non-functionalized monomers (3-
hydroxyoctanoate and 3-hydroxyhexanoate monomers).  
Fig. 2. PHACOS and PHO disks and biofilm formation. (a) ESEM of S. aureus
T
 and P. aeruginosa biofilms. 
(b) Crystal violet staining assay for biofilm quantification. The capacity of biofim formation on control PET 
disks is considered 100%. (c) Bacterial viability, CFU counts. 
Fig. 3. Compararison of antiadherent and antibacterial activities of PHACOS and PHO surfaces on S. 
aureus
T
. Fluorescence microscopy using Bacterial Viability test on PHACOS (a) and PHO (b). (c) 
Measurement of antibacterial activity of polymer (PHACOS and PHO) surfaces. R = 1 means 10-fold less 
viable cells recovered from sample disk after 24 h when compared to the control disk. The ISO 
22196:2011 stated conditions were fully satisfied in term of statistics. 
Fig. 4. In vitro determination of PHACOS and PHO cytotoxicity and immunocompatibility. (a) Determination 
of PHO cytotoxic effect on mouse RAW 264.7 macrophages by MTT assay. Negative control extracts were 
incubated with PET disks. Positive control cells were treated with LPS to monitor the decrease in cell 
viability. (b) Determination of PHACOS cytotoxic effect on RAW 264.7 macrophages. (c) Determination of 
PHO and PHACOS cytotoxic effect on mouse fibroblasts (BALB 3T3). Control extracts were incubated with 
PET disks. (d) Griess test. Inflammatory activity of PHACOS and PHO on RAW 264.7 macrophages 
measured as increase of NO production, Open, light gray, dark gray, and black bars represent, 
respectively, positive control (cells treated with LPS), negative control (extracts incubated with PET), 
incubated with PHACOS, incubated with PHO.  
Fig. 5. AB assay for determination of BALB 3T3 fibroblasts in vitro proliferation on PHACOS (grey bars) 
and PHO surfaces (black bars). White bars represent PET control. 
Fig. 6. In vivo ROS imaging of PHACOS and PHO implant-associated inflamation after subcutaneous 
administration of H-ICG. (a) Bioimaging data of animals. (b) Quantification of bioimaging ROS 
fluorescence data of mice with PHACOS and PHO implants incubated with S. aureus
T
 and sterile 
PHACOS and PHO implants (*P < 0.05 between sham and implant, n > 3 mice/time point for sham and 
implant groups).  
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Fig. 7. Immunohistochemical staining for macrophages and neutrophils in implant-associated 
inflammation. (a) Representative co-localization images of macrophages (CD68
+
; green) and nuclei (DAPI; 
blue) in 14-d: sterile PHO; S. aureus
T
 precolonized PHO; sterile PHACOS; S. aureus precolonized 
PHACOS implants (from left to right). (b) Intracellular ROS (H-Cy5+, red) co-localizing with macrophages 
in: sterile PHO; S. aureus
T
 pre-colonized PHO; sterile PHACOS; S. aureus
T
 pre-colonized PHACOS 
implants (from left to right). (c) Neutrophils (NIMP-R14
+
; green) with DAPI in 14-d: sterile PHO; S. aureus 
precolonized PHO; sterile PHACOS; S. aureus
T
 precolonized PHACOS implants. (d) Intracellular ROS (H-
Cy5+, red) co-localizing with neutrophils in: sterile PHO; S. aureus
T
 pre-colonized PHO; sterile PHACOS; 
S. aureus
T
 pre-colonized PHACOS implants (from left to right). (e) Quantification of CD68
+
 (left) and NIMP-
R14 cells (right) stained positive for CD68
+
 (macrophages) and for NIMP-R14
+
 cells (neutrophiles) (n = 3 
mice/time point; *P < 0.05 between macrophage recruitment to S. aureus
T
 pre-colonized PHO and S. 
aureus
T
 pre-colonized PHACOS implant; neutrophil recruitment to sterile PHO and sterile PHACOS 
implants; neutrophil recruitment to S. aureus
T
 pre-colonized PHO and S. aureus
T
 pre-colonized PHACOS). 
(f) Quantification of CD68
+
 and ROS
+ 
(left) and NIMP-R14 and ROS
+
 (right) cells co-localization (n = 3 
mice/time point; *P < 0.05 between ROS active macrophage on sterile PHO and sterile PHACOS implant; 
ROS active macrophage on S. aureus
T
 pre-colonized PHO and S. aureus
T
 pre-colonized PHACOS 
implant; ROS active neutrophil on sterile PHO and S. aureus
T
 pre-colonized PHO; ROS active neutrophil 
on sterile PHACOS and S. aureus
T
 pre-colonized PHACOS implant). 
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Table S1.  
Antibiotic resistance of MRSA clinical isolates 
Antibiotic MIC (µg/mL) 
 61286 61115 61314 
Ampicillin >4 >4 >4 
Ciprofloxacin 1 >16 1 
Clindamycin 8 ≤0.25 8 
Erythromycin >32 >32 2 
Gentamicin ≤0.5 8 ≤0.5 
Oxacillin >16 >16 >16 
Rifampicin ≤0.5 ≤0.5 ≤0.5 
Teicoplanin 1 2 64 
Vancomycin 1 2 12 
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